|Mr. Remi Barbier||Founder, Chairman, Pres & CEO||936.12k||N/A||1960|
|Mr. Eric J. Schoen||Chief Financial Officer||251.93k||N/A||1968|
|Dr. Nadav Friedmann||Chief Medical Officer & Director||345k||N/A||1943|
|Dr. George Thornton||Sr. VP of Technology||N/A||N/A||N/A|
|Mr. Michael Zamloot||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Dr. Lindsay H. Burns Ph.D.||Sr. VP of Neuroscience||N/A||N/A||N/A|
|Dr. James W. Kupiec M.D.||Chief Clinical Devel. Officer||N/A||N/A||N/A|
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc.’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder rights: 8; Compensation: 8.